Komboglyze

Country: European Union

Language: Maltese

Source: EMA (European Medicines Agency)

Active ingredient:

metformin hydrochloride, saxagliptin hydrochloride

Available from:

AstraZeneca AB 

ATC code:

A10BD10

INN (International Name):

saxagliptin, metformin hydrochloride

Therapeutic group:

Drugs used in diabetes, Combinations of oral blood glucose lowering drugs

Therapeutic area:

Diabetes Mellitus, Tip 2

Therapeutic indications:

Komboglyze huwa indikat kif frozen tad-dieta u jeżerċitaw biex jitjieb il-kontroll ta ' glycaemic fil-pazjenti adulti età 18-il sena u aktar antiki ma tip-2 diabetes mellitus jirriżultax kkontrollata tagħhom bħala tollerat tad-doża ta ' metformin waħdu jew dawk diġà qed ittrattati bil-kombinazzjoni ta ' saxagliptin u metformin bħala pilloli separati. Komboglyze huwa indikat ukoll f'kumbinazzjoni ma ' l-insulina (i. terapija ta ' kumbinazzjoni tripla) bħala żieda mad-dieta u l-eżerċizzju biex itejjeb il-kontroll gliċemiku f'pazjenti adulti minn 18-il sena u akbar b'dijabete tat-tip 2 mellitus meta l-insulina u metformin waħdu ma jipprovdux kontroll gliċemiku adegwat.

Product summary:

Revision: 20

Authorization status:

Awtorizzat

Authorization date:

2011-11-24

Patient Information leaflet

                                43
B. FULJETT TA’ TAGĦRIF
44
FULJETT TA’ TAGĦRIF: INFORMAZZJONI GĦALL-UTENT
KOMBOGLYZE 2.5 MG/850 MG PILLOLI MIKSIJIN B’RITA
saxagliptin/metformin hydrochloride
AQRA SEW DAN IL-FULJETT KOLLU QABEL TIBDA TIEĦU DIN IL-MEDIĊINA
PERESS LI FIH INFORMAZZJONI
IMPORTANTI GĦALIK.

Żomm dan il-fuljett. Jista’ jkollok bżonn terġa’ taqrah.

Jekk ikollok aktar mistoqsijiet, staqsi lit-tabib, lill-ispiżjar jew
l-infermier tiegħek.

Din il-mediċina ġiet mogħtija lilek biss. M’għandekx tgħaddiha
lil persuni oħra. Tista’
tagħmlilhom il-ħsara, anki jekk ikollhom l-istess sinjali ta’ mard
bħal tiegħek.

Jekk ikollok xi effett sekondarju kellem lit-tabib, lill-ispiżjar jew
lill-infermier tiegħek.
Dan jinkludi xi effett sekondarju possibbli li m’huwiex elenkat
f’dan il-fuljett. Ara
sezzjoni 4.
F’DAN IL-FULJETT:
1.
X’inhu Komboglyze u għalxiex jintuża
2.
X’għandek tkun taf qabel ma tieħu Komboglyze
3.
Kif għandek tieħu Komboglyze
4.
Effetti sekondarji possibbli
5.
Kif taħżen Komboglyze
6.
Kontenut tal-pakkett u informazzjoni oħra
1.
X’INHU KOMBOGLYZE U GĦALXIEX JINTUŻA
Din il-mediċina fiha żewġ mediċini differenti li jissejħu:
saxagliptin, parti minn klassi ta’ mediċini li jissejħu inibituri
tad-DPP-4 (inibituri ta’
dipeptidyl peptidase-4), u metformin, parti minn klassi ta’
mediċini li jissejħu biguanides.
It-tnejn li huma jgħamlu parti minn grupp ta’ mediċini li
jissejħu sustanzi kontra d-dijabete li
jittieħdu mill-ħalq.
GĦAL XIEX JINTUŻA KOMBOGLYZE
Din il-mediċina tintuża għall-kura ta’ tip ta’ dijabete li
tissejjaħ ‘dijabete tat-tip 2’.
KIF JAĦDEM KOMBOGLYZE
Saxagliptin u metformin jaħdmu flimkien biex ibaxxu z-zokkor fid-demm
tiegħek. Iżidu l-
livell tal-insulina wara ikla. Ibaxxu wkoll l-ammont ta’ zokkor li
jagħmel ġismek. Flimkien
mad-dieta u l-eżerċizzju, dan jgħin biex ibaxxilek iz-zokkor
fid-demm tiegħek. Din il-
mediċina tista’ tintuża waħidha jew flimkien ma’ mediċini
antidijabetiċi, inkluż m
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ANNESS I
SOMMARJU TAL-KARATTERISTIĊI TAL-PRODOTT
2
1.
ISEM IL-PRODOTT MEDIĊINALI
Komboglyze 2.5 mg/850 mg pilloli miksijin b’rita
Komboglyze 2.5 mg/1,000 mg pilloli miksijin b’rita
2.
GĦAMLA KWALITATTIVA U KWANTITATTIVA
Komboglyze 2.5 mg/850 mg pilloli miksijin b’rita
Kull pillola fiha 2.5 mg ta’ saxagliptin (bħala l-hydrochloride) u
850 mg ta’ metformin
hydrochloride.
Komboglyze 2.5 mg/1,000 mg pilloli miksijin b’rita
Kull pillola fiha 2.5 mg ta’ saxagliptin (bħala l-hydrochloride) u
1,000 mg ta’ metformin
hydrochloride.
Għal-lista kompluta ta’ eċċipjenti, ara sezzjoni 6.1.
3.
GĦAMLA FARMAĊEWTIKA
Pillola miksija b’rita (pillola)
Komboglyze 2.5 mg/850 mg pilloli miksijin b’rita
Pilloli kannella ċar għal kannella, konvessi miż-żewġ naħat,
tondi, miksijin b’rita,
b’“2.5/850” ittimbrati fuq naħa u “4246” ittimbrata fuq
in-naħa l-oħra, b’linka ċelesti.
Komboglyze 2.5 mg/1,000 mg pilloli miksijin b’rita
Pilloli isfar pallidu għal isfar ċar, konvessi miż-żewġ naħat,
f’forma ovvali, miksijin b’rita,
b’“2.5/1000” ittimbrati fuq naħa u “4247” ittimbrata fuq
in-naħa l-oħra, b’linka ċelesti.
4.
TAGĦRIF KLINIKU
4.1
INDIKAZZJONIJIET TERAPEWTIĊI
Komboglyze huwa indikat f’adulti b’dijabete mellitus tat-tip 2
bħala aġġunt mad-dieta u l-
eżerċizzju biex itejjeb il-kontroll taz-zokkor fid-demm:

f’pazjenti li ma jkunux ikkontrollati kif jixraq bl-aktar doża
għolja tollerata
b’metformin waħdu

f’taħlita ma’ prodotti mediċinali oħra għall-kura
tad-dijabete, inkluż mal-insulina,
f’pazjenti li ma jkunux ikkontrollati kif jixraq b’metformin u
b’dawn il-prodotti
mediċinali (ara sezzjonijiet 4.4, 4.5 u 5.1 għal dejta disponibbli
dwar taħlitiet differenti)

f’pazjenti li diġà qed jingħataw kura b’taħlita ta’
saxagliptin u metformin bħala pilloli
separati.
.
4.2
POŻOLOĠIJA U METODU TA’ KIF GĦANDU JINGĦATA
Pożoloġija
_Adulti b’funzjoni renali normali (GFR≥90 mL/min)_
3
_Għall-pazjenti li 
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 30-05-2023
Summary of Product characteristics Summary of Product characteristics Bulgarian 30-05-2023
Public Assessment Report Public Assessment Report Bulgarian 02-08-2017
Patient Information leaflet Patient Information leaflet Spanish 30-05-2023
Public Assessment Report Public Assessment Report Spanish 02-08-2017
Patient Information leaflet Patient Information leaflet Czech 30-05-2023
Public Assessment Report Public Assessment Report Czech 02-08-2017
Patient Information leaflet Patient Information leaflet Danish 30-05-2023
Public Assessment Report Public Assessment Report Danish 02-08-2017
Patient Information leaflet Patient Information leaflet German 30-05-2023
Public Assessment Report Public Assessment Report German 02-08-2017
Patient Information leaflet Patient Information leaflet Estonian 30-05-2023
Public Assessment Report Public Assessment Report Estonian 02-08-2017
Patient Information leaflet Patient Information leaflet Greek 30-05-2023
Public Assessment Report Public Assessment Report Greek 02-08-2017
Patient Information leaflet Patient Information leaflet English 30-05-2023
Public Assessment Report Public Assessment Report English 02-08-2017
Patient Information leaflet Patient Information leaflet French 30-05-2023
Public Assessment Report Public Assessment Report French 02-08-2017
Patient Information leaflet Patient Information leaflet Italian 30-05-2023
Public Assessment Report Public Assessment Report Italian 02-08-2017
Patient Information leaflet Patient Information leaflet Latvian 30-05-2023
Public Assessment Report Public Assessment Report Latvian 02-08-2017
Patient Information leaflet Patient Information leaflet Lithuanian 30-05-2023
Summary of Product characteristics Summary of Product characteristics Lithuanian 30-05-2023
Public Assessment Report Public Assessment Report Lithuanian 02-08-2017
Patient Information leaflet Patient Information leaflet Hungarian 30-05-2023
Summary of Product characteristics Summary of Product characteristics Hungarian 30-05-2023
Public Assessment Report Public Assessment Report Hungarian 02-08-2017
Patient Information leaflet Patient Information leaflet Dutch 30-05-2023
Public Assessment Report Public Assessment Report Dutch 02-08-2017
Patient Information leaflet Patient Information leaflet Polish 30-05-2023
Public Assessment Report Public Assessment Report Polish 02-08-2017
Patient Information leaflet Patient Information leaflet Portuguese 30-05-2023
Summary of Product characteristics Summary of Product characteristics Portuguese 30-05-2023
Public Assessment Report Public Assessment Report Portuguese 02-08-2017
Patient Information leaflet Patient Information leaflet Romanian 30-05-2023
Public Assessment Report Public Assessment Report Romanian 02-08-2017
Patient Information leaflet Patient Information leaflet Slovak 30-05-2023
Public Assessment Report Public Assessment Report Slovak 02-08-2017
Patient Information leaflet Patient Information leaflet Slovenian 30-05-2023
Summary of Product characteristics Summary of Product characteristics Slovenian 30-05-2023
Public Assessment Report Public Assessment Report Slovenian 02-08-2017
Patient Information leaflet Patient Information leaflet Finnish 30-05-2023
Public Assessment Report Public Assessment Report Finnish 02-08-2017
Patient Information leaflet Patient Information leaflet Swedish 30-05-2023
Public Assessment Report Public Assessment Report Swedish 02-08-2017
Patient Information leaflet Patient Information leaflet Norwegian 30-05-2023
Summary of Product characteristics Summary of Product characteristics Norwegian 30-05-2023
Patient Information leaflet Patient Information leaflet Icelandic 30-05-2023
Summary of Product characteristics Summary of Product characteristics Icelandic 30-05-2023
Patient Information leaflet Patient Information leaflet Croatian 30-05-2023
Public Assessment Report Public Assessment Report Croatian 02-08-2017

View documents history